TORONTO, Aug. 13, 2012 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH, NASDAQ:TTHI) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer
of Transition will be presenting at the Canaccord Genuity Annual Growth
Conference on Thursday, August 16th, 2012 at 2:00 p.m. Eastern Time at
the Intercontinental Boston Hotel in Boston, Massachusetts.
Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. Transition's lead product
is ELND005 (AZD-103) for the treatment of Alzheimer's disease and
Transition also has an emerging pipeline of innovative preclinical and
clinical drug candidates. The other drugs in the pipeline that the
Company is developing are for anti-inflammatory and metabolic
indications. Transition's shares are listed on the NASDAQ under the
symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH".
For additional information about the Company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be
superseded by more recent information we have disclosed in later press
releases, filings with the OSC, SEC or otherwise. Except for historical
information, this press release may contain forward-looking statements,
relating to expectations, plans or prospects for Transition, including
conducting clinical trials and potential efficacy of its products.
These statements are based upon the current expectations and beliefs of
Transition's management and are subject to certain risks and
uncertainties that could cause actual results to differ materially from
those described in the forward-looking statements. These risks and
uncertainties include factors beyond Transition's control and the risk
factors and other cautionary statements discussed in Transition's
quarterly and annual filings with the Canadian commissions.
SOURCE Transition Therapeutics Inc.